PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.
Metastases directed therapy (MDT)
Oligometastatic prostate cancer (OMPC)
PET/CT
Prostate specific membrane antigen (PSMA)
Response assessment
Journal
EJNMMI reports
ISSN: 3005-074X
Titre abrégé: EJNMMI Rep
Pays: England
ID NLM: 9918752082606676
Informations de publication
Date de publication:
19 Aug 2024
19 Aug 2024
Historique:
received:
04
03
2024
accepted:
14
05
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
epublish
Résumé
Bone metastases are very common in advanced prostate cancer and can sensitively be detected utilizing PSMA-PET/CT. Therefore, our goal was to evaluate the suitability of PSMA-PET/CT-guided metastasis-directed external beam radiotherapy (MDT) as treatment option for patients with biochemical recurrence and oligometastatic bone lesions. We retrospectively examined 32 prostate cancer patients with biochemical recurrence and PSMA-positive oligometastatic disease limited to the bone (n = 1-3). A total of 49 bone lesions were treated with MDT. All patients received a post-radiotherapy PSMA-PET/CT-Scan. Changes in SUV MDT lead to a SUV MDT is a very effective treatment modality for prostate cancer bone oligometastases and lesion response to MDT can be assessed using the (semi-)quantitative parameters SUV
Identifiants
pubmed: 39155339
doi: 10.1186/s41824-024-00212-w
pii: 10.1186/s41824-024-00212-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25Informations de copyright
© 2024. The Author(s).
Références
Anderson EM, McBride SM (2022) The Use of Androgen Deprivation Therapy in Combination with Radiation for localized prostate Cancer. Front Urol 2:890814
doi: 10.3389/fruro.2022.890814
Baumann R et al (2018) Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol 194(4):318–324
doi: 10.1007/s00066-017-1239-1
pubmed: 29181556
Boellaard R et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Cornford P et al (2017) EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol 71(4):630–642
doi: 10.1016/j.eururo.2016.08.002
pubmed: 27591931
Cornford P et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263–282
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33039206
Deek MP, Phillips RM, Tran PT (2021) Local therapies in Oligometastatic and oligoprogressive prostate Cancer. Semin Radiat Oncol 31(3):242–249
doi: 10.1016/j.semradonc.2021.03.007
pubmed: 34090651
pmcid: 8189311
Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Erdi YE et al (1995) Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Cancer Res 55(23Supplement):5823s–5826s
pubmed: 7493353
Erdi YE et al (1997) Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer: Interdisciplinary Int J Am Cancer Soc 80(S12):2505–2509
doi: 10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F
Fanti S, Hadaschik B, Herrmann K (2020) Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria. Soc Nuclear Med. pp. 678–682
Fanti S et al (2021) Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469–476
doi: 10.1007/s00259-020-04934-4
pubmed: 32617640
Fendler WP et al (2017) 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014–1024
doi: 10.1007/s00259-017-3670-z
pubmed: 28283702
Gafita A et al (2022) Novel Framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate Cancer (RECIP 1.0): an International Multicenter Study. J Nucl Med 63(11):1651–1658
pubmed: 35422442
pmcid: 9635677
Gandaglia G et al (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210–216
doi: 10.1002/pros.22742
pubmed: 24132735
Grünig H et al (2021) Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging 48(13):4483–4494
doi: 10.1007/s00259-021-05424-x
pubmed: 34120201
pmcid: 8566387
Gundem G et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357
doi: 10.1038/nature14347
pubmed: 25830880
pmcid: 4413032
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10.
Henkenberens C et al (2020) Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlenther Onkol 196(11):1006–1017
doi: 10.1007/s00066-020-01629-5
pubmed: 32399639
pmcid: 7581615
Hofman MS et al (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38(1):200–217
doi: 10.1148/rg.2018170108
pubmed: 29320333
Hurmuz P et al (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09 – 002). Strahlentherapie und Onkologie, pp. 1034–1043
Kesch C et al (2017) 68Ga or 18F for prostate cancer imaging? J Nucl Med 58(5):687–688
doi: 10.2967/jnumed.117.190157
pubmed: 28408526
Kuten J et al (2019) [68Ga] Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 9(1):1–8
doi: 10.1186/s13550-019-0554-1
Lawhn-Heath C et al (2019) Single-center prospective evaluation of 68Ga-PSMA-11 PET in biochemical recurrence of prostate cancer. Am J Roentgenol 213(2):266–274
doi: 10.2214/AJR.18.20699
Lievens Y et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol 148:157–166
doi: 10.1016/j.radonc.2020.04.003
Locke JA et al (2015) Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat Reviews Urol 12(4):193–204
doi: 10.1038/nrurol.2015.50
Macedo F et al (2017) Bone metastases: an overview. Oncol Reviews, 11(1)
Malaspina S et al (2023) Flare on [18F] PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 50(2):613–621
doi: 10.1007/s00259-022-05970-y
pubmed: 36161511
Mingels C et al (2022) Diagnostic accuracy of [18F] PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 49(7):2436–2444
doi: 10.1007/s00259-022-05693-0
pubmed: 35067735
pmcid: 9165245
Mittlmeier LM et al (2021) Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET/CT imaging in prostate cancer patients. Front Oncol, : p. 1612
Onal C et al (2021) Oligometastatic bone disease in castration-sensitive prostate Cancer patients treated with stereotactic body Radiotherapy using 68Ga-PSMA PET/CT: TROD 09 – 004 study. Clin Nucl Med 46(6):465–470
doi: 10.1097/RLU.0000000000003558
pubmed: 33661210
Oprea-Lager DE et al (2021) Bone metastases are measurable: the role of whole-body MRI and Positron Emission Tomography. Front Oncol 11(November):1–18
Ost P et al (2016) Progression-free Survival following stereotactic body radiotherapy for oligometastatic prostate Cancer Treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69(1):9–12
doi: 10.1016/j.eururo.2015.07.004
pubmed: 26189689
Ost P et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Palma DA et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830–2838
doi: 10.1200/JCO.20.00818
pubmed: 32484754
pmcid: 7460150
Perera M et al (2020) Gallium-68 prostate-specific membrane Antigen Positron Emission Tomography in Advanced prostate Cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane Antigen-avid lesions: a systematic review and Meta. Eur Urol 77(4):403–417
doi: 10.1016/j.eururo.2019.01.049
pubmed: 30773328
Phelps TE et al (2023) Predicting outcomes of Indeterminate Bone lesions on 18F-DCFPyL PSMA PET/CT scans in the setting of high-risk primary or recurrent prostate Cancer. J Nucl Med 64(3):395–401
doi: 10.2967/jnumed.122.264334
pubmed: 36265908
Phillips R et al (2020) Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial. JAMA Oncol 6(5):650–659
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Reyes DK et al (2020) Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol 37(7):1–12
doi: 10.1007/s12032-020-01385-7
Rogowski P et al (2021a) Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol 16(1):1–11
doi: 10.1186/s13014-021-01849-8
Rogowski P et al (2021b) Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging
Rogowski P et al (2022) Radiotherapy in oligometastatic prostate cancer—a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 198(8):727–734
doi: 10.1007/s00066-022-01925-2
pubmed: 35364690
pmcid: 9300519
Seifert R et al (2023a) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol
Seifert R et al (2023b) Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med 64(5):738–743
doi: 10.2967/jnumed.118.215434
pubmed: 36460340
Sung H et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
Tang C et al (2023) Addition of Metastasis-Directed therapy to intermittent hormone therapy for oligometastatic prostate Cancer: the EXTEND phase 2 Randomized Clinical Trial. JAMA Oncol
Thomas C, Schrader A (2023) Neue S3-Leitlinie Prostatakarzinom 2021 (Version 6.2)–Was hat sich beim fortgeschrittenen Prostatakarzinom geändert? Die Urologie 62(2):171–175
doi: 10.1007/s00120-022-01927-z
pubmed: 36066611
Vaz S et al (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Springer, pp 9–15
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, (2013) 310(20): p. 2191–2194
Zacho HD et al (2018) 68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging 38(6):911–922
doi: 10.1111/cpf.12480
Zacho HD et al (2020) Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res, 10(1)